.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: Standard of Care for Treatment of DLBCL

July 15th 2020

EP. 2: Prognosis of R/R DLBCL

July 15th 2020

EP. 3: Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

EP. 4: Role of CAR T-cell Therapy in R/R DLBCL

July 15th 2020

EP. 5: ASCO 2020 Data: CAR T in R/R DLBCL

July 15th 2020

EP. 6: CAR T in R/R DLBCL: Safety and Patient Selection

July 15th 2020

EP. 7: CD19-Directed Therapies for Treatment of R/R DLBCL

July 15th 2020

EP. 8: Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

July 15th 2020

EP. 9: Safety and Efficacy of Oral Agents in R/R DLBCL

July 15th 2020

EP. 10: Emerging Therapies for R/R DLBCL

July 15th 2020

EP. 11: Improving Outcomes in Patients With R/R DLBCL

July 15th 2020

EP. 12: Closing Thoughts on Treatment of R/R DLBCL

July 15th 2020